18400508

Source:http://linkedlifedata.com/resource/pubmed/id/18400508

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001792, umls-concept:C0030705, umls-concept:C0036043, umls-concept:C0036525, umls-concept:C0599755, umls-concept:C0995188, umls-concept:C1514923, umls-concept:C1522484, umls-concept:C1527249
pubmed:issue	3
pubmed:dateCreated	2008-8-12
pubmed:abstractText	Few data are available from clinical trials for elderly patients receiving cetuximab.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8916049
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/cetuximab, http://linkedlifedata.com/resource/pubmed/chemical/irinotecan, http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1040-8428
pubmed:author	pubmed-author:AndruDD, pubmed-author:BacherJ DJD, pubmed-author:BouchahdaMM, pubmed-author:DomontJJ, pubmed-author:KarabouéAA, pubmed-author:LandaJJ, pubmed-author:LevyVV, pubmed-author:LledoGG, pubmed-author:MacarullaTT, pubmed-author:RougierPP, pubmed-author:SpanoJ PJP, pubmed-author:TaberneroJJ
pubmed:issnType	Print
pubmed:volume	67
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	255-62
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:18400508-Aged, pubmed-meshheading:18400508-Aged, 80 and over, pubmed-meshheading:18400508-Antibodies, Monoclonal, pubmed-meshheading:18400508-Antineoplastic Agents, pubmed-meshheading:18400508-Antineoplastic Agents, Phytogenic, pubmed-meshheading:18400508-Camptothecin, pubmed-meshheading:18400508-Clinical Trials as Topic, pubmed-meshheading:18400508-Cohort Studies, pubmed-meshheading:18400508-Colorectal Neoplasms, pubmed-meshheading:18400508-Drug Administration Schedule, pubmed-meshheading:18400508-Drug Therapy, Combination, pubmed-meshheading:18400508-Female, pubmed-meshheading:18400508-Humans, pubmed-meshheading:18400508-Male, pubmed-meshheading:18400508-Multicenter Studies as Topic, pubmed-meshheading:18400508-Neoplasm Metastasis, pubmed-meshheading:18400508-Organoplatinum Compounds, pubmed-meshheading:18400508-Pyrimidines, pubmed-meshheading:18400508-Receptor, Epidermal Growth Factor, pubmed-meshheading:18400508-Registries, pubmed-meshheading:18400508-Retrospective Studies, pubmed-meshheading:18400508-Treatment Outcome
pubmed:year	2008
pubmed:articleTitle	Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.
pubmed:affiliation	Hôpital Paul Brousse,Villejuif, Paris, France.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't